Elimusertib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Elimusertib
- DrugBank Accession Number
- DB19041
- Background
Elimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 375.436
Monoisotopic: 375.180758324 - Chemical Formula
- C20H21N7O
- Synonyms
- 1,7-naphthyridine, 2-((3r)-3-methyl-4-morpholinyl)-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-3-yl)-
- External IDs
- BAY-1895344
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7N13IK9LNH
- CAS number
- 1876467-74-1
- InChI Key
- YBXRSCXGRPSTMW-CYBMUJFWSA-N
- InChI
- InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1
- IUPAC Name
- SMILES
- C[C@@H]1COCCN1C1=NC2=C(N=CC=C2C(=C1)C1=CC=NN1C)C1=CC=NN1
References
- General References
- Not Available
- External Links
- ChemSpider
- 64854199
- ChEMBL
- CHEMBL4647810
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1, 2 Active Not Recruiting Treatment Recurrent Alveolar Rhabdomyosarcoma / Recurrent Ewing's Sarcoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Refractory Alveolar Rhabdomyosarcoma / Refractory Ewing Sarcoma / Refractory Lymphomas / Refractory Malignant Solid Neoplasm 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 02, 2024 18:44 / Updated at July 03, 2024 00:11